Abstract:G protein-coupled receptor 119 (GPR119) is expressed in β cells and enteroendocrine L cells. In this study, we investigated whether PSN632408 (PSN), a small molecular GPR119 agonist, can stimulate human β cell regeneration in culture and improve human β cell function and stimulate human β cell regeneration in vivo using humanized mice. To determine β cell replication in culture, human islets isolated from a 14 year-old donor were cultured for 4 days, with and without PSN. BrdU was added on day 3 for overnight. Insulin and BrdU double immunostaining was performed on intact islets. Insulin+and BrdU+ β cells were accounted using confocal microscope. For in vivo study, immunodeficient NOD.scid mice were rendered diabetic by STZ. Human islets (1500 IE) with low endocrine purity (15% β cells, 8% α cells, and 24% duct cells) were transplanted under the left kidney capsule of each diabetic NOD.scid mouse. Islets from 4 donors were used for transplantation. The recipient mice were treated with vehicle or PSN (10 mg/kg/day) along with BrdU daily starting from the day of transplantation. At 2 weeks, 43% PSN632408-treated mice (n=21) achieved normoglycaemia, while none vehicle-treated mice (n=17) reversed diabetes. At 4 weeks, 71% PSN-treated mice achieved normoglycemia which was significantly higher than vehicle-treated mice (23%, P<0.001) and the mean blood glucose levels were 260±46.9 mg/dL in PSN-treated mice and 527±24.2 mg/dL in vehicle-treated mice. PSN-treated mice significantly improved glucose tolerance at 15, 30 and 60 minutes after oral glucose challenge as compared to vehicle-treated mice (P<0.05). The percentage of insulin+/BrdU+ cells in islet grafts was 6.3±0.5% in PSN632408-treated mice and 1.5±0.2% in vehicle-treated mice (P<0.01). The percentage of insulin+/Ki67+ cells in islet grafts was 2.9±0.3% in PSN632408-treated mice and 0.7±0.09% in vehicle-treated mice (P<0.05). Moreover, PSN treatment also increased β cell neogenesis as evident by significant increase of both insulin+/CK19+ cells (3.6±0.3%), compared to controls (1.2±0.3%, P<0.05). Our data demonstrates that GPR119 agonist can improve human islet function and stimulate human β cell regeneration.

Targeted Derivation of Organotypic Glucose- and GLP-1-Responsive Β Cells Prior to Transplantation into Diabetic Recipients.

Successful β cells islet regeneration in streptozotocin-induced diabetic baboons using ultrasound-targeted microbubble gene therapy with cyclinD2/CDK4/GLP1.

Successful Β Cells Islet Regeneration in Streptozotocin-Induced Diabetic Baboons Using Ultrasound-Targeted Microbubble Gene Therapy with Cyclind2/cdk4/glp1

Human Expandable Pancreatic Progenitor–derived Β Cells Ameliorate Diabetes

Successful Β Cells Islet Regeneration Instreptozotocin-Induced Diabetic Baboons Usingultrasound-Targeted Microbubble Gene Therapywith Cyclind2/cdk4/glp1

In Vitro Expansion of Pancreatic Islet Clusters Facilitated by Hormones and Chemicals.

Chemical Combinations Potentiate Human Pluripotent Stem Cell-Derived 3D Pancreatic Progenitor Clusters Toward Functional Β Cells

Small Molecules Facilitate the Reprogramming of Mouse Fibroblasts into Pancreatic Lineages

Forward programming of hiPSCs towards beta-like cells using Ngn3, Pdx1, and MafA

Generation of Insulin-Producing Cells from PDX-1 Gene-Modified Human Mesenchymal Stem Cells.

Chemical Strategies for Pancreatic Β Cell Differentiation, Reprogramming, and Regeneration

Differentiation and Transplantation of Functional Pancreatic Beta Cells Generated from Induced Pluripotent Stem Cells Derived from a Type 1 Diabetes Mouse Model

Generation of Insulin-Producing Cells from Bone Marrow Mesenchymal Stem Cells with Modified Expression of PDX1 and NKX6.1

Optimized Protocol for Generating Functional Pancreatic Insulin-secreting Cells from Human Pluripotent Stem Cells

Generation of Human Stem Cell-Derived Pancreatic Organoids (POs) for Regenerative Medicine

The Reversal of Hyperglycaemia in Diabetic Mice Using Plga Scaffolds Seeded with Islet-Like Cells Derived from Human Embryonic Stem Cells

Generation of Insulin-Producing Cells from PDX1 and NKX6.1 Gene-Modified Bone Marrow Mesenchymal Stem Cells

Strategies to Improve the Safety of iPSC-Derived β Cells for β Cell Replacement in Diabetes

Directed differentiation of human iPSC into insulin producing cells is improved by induced expression of PDX1 and NKX6.1 factors in IPC progenitors

A Small Molecular GPR119 Agonist Improves Human Beta Cell Function and Stimulates Human Beta Cell Regeneration in Humanized Mice.

Acquisition of Dynamic Function in Human Stem Cell-Derived β Cells